What is Zacks Research’s Forecast for ESLA Q2 Earnings?

Estrella Immunopharma, Inc. (NASDAQ:ESLA) – Equities research analysts at Zacks Research issued their Q2 2026 EPS estimates for shares of Estrella Immunopharma in a report released on Tuesday, July 14th. Zacks Research analyst D. Bautz forecasts that the company will post earnings of ($0.09) per share for the quarter. The consensus estimate for Estrella Immunopharma’s current full-year earnings is ($0.29) per share. Zacks Research also issued estimates for Estrella Immunopharma’s Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at ($0.07) EPS and FY2026 earnings at ($0.29) EPS.

Estrella Immunopharma (NASDAQ:ESLA) last released its quarterly earnings results on Saturday, May 16th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.03.

Separately, Weiss Ratings raised Estrella Immunopharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, June 12th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $8.00.

Estrella Immunopharma Price Performance

Shares of NASDAQ ESLA opened at $0.84 on Friday. The business has a 50-day moving average of $1.04 and a two-hundred day moving average of $1.20. The company has a market capitalization of $36.15 million, a price-to-earnings ratio of -2.47 and a beta of 0.85. Estrella Immunopharma has a 1 year low of $0.73 and a 1 year high of $3.15.

Institutional Investors Weigh In On Estrella Immunopharma

Several hedge funds and other institutional investors have recently bought and sold shares of ESLA. XTX Topco Ltd lifted its holdings in Estrella Immunopharma by 376.9% in the 4th quarter. XTX Topco Ltd now owns 49,472 shares of the company’s stock valued at $77,000 after acquiring an additional 39,099 shares during the last quarter. Quadrature Capital Ltd acquired a new position in shares of Estrella Immunopharma in the 4th quarter worth approximately $43,000. Marshall Wace LLP acquired a new position in shares of Estrella Immunopharma in the 4th quarter worth approximately $88,000. State Street Corp raised its holdings in shares of Estrella Immunopharma by 93.5% in the 4th quarter. State Street Corp now owns 43,252 shares of the company’s stock worth $67,000 after purchasing an additional 20,900 shares in the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of Estrella Immunopharma by 1,045.7% in the 4th quarter. Renaissance Technologies LLC now owns 122,468 shares of the company’s stock worth $191,000 after purchasing an additional 111,779 shares in the last quarter. 0.35% of the stock is currently owned by institutional investors.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.